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The collecting duct (CD) expresses considerable amounts of PPARδ. While its role is unknown in the CD, in other renal cells it has
been shown to regulate both growth and apoptosis. We thus hypothesized that PPARδ reduces apoptotic responses and stimulates
cell growth in the mouse CD, and examined the eﬀect of GW501516, a synthetic PPARδ ligand, on these responses in mouse
IMCD-K2 cells. High doses of GW501516 decreased both DNA and protein synthesis in these cells by 80%, but had no overall
eﬀect on cell viability. Although anisomycin treatment resulted in an increase of caspase-3 levels of about 2.59-fold of control,
GW501516 did not aﬀect anisomycin-induced changes in active caspase-3 levels. These results show that a PPARδ ligand inhibits
growth but does not aﬀect anisomycin-apoptosis in a mouse IMCD cell line. This could have therapeutic implications for renal
diseases associated with increased CD growth responses.
Copyright © 2009 Jordan Clark et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Traditional prostaglandin (PG) signaling in renal epithelial
cells occurs through activation of prostanoid receptors [1–
3]. In recent years, however, a novel signaling pathway for
PGs has been found in which ligand-activated transcription
factors called peroxisome proliferator-activated receptors
(PPARs) [4] are activated at the nuclear membrane. One
PPAR type, PPARδ, also known as PPARβ,i su b i q u i -
tously expressed in almost every tissue examined [5]. Both
prostanoids PGI2 and PGE2 have been known to activate
PPARδ [6, 7]. The main role of PPARδ is in cell survival and
this has been well characterized in colon cancer [8–10].
In the kidney, PPARδ i sf o u n di ne v e r yp a r to ft h e
nephron with high levels in the glomerulus, cortical col-
lecting duct, and inner medullary collecting duct (IMCD)
and low expression in the outer medullary collecting duct.
This PPAR has been implicated in the renal complications
of metabolic syndrome [11], but most studies describe
a link between PPARδ and survival of renal cells. In a
s t u d yb yH a oe ta l .[ 6], PPARδ was shown to increase
renal medullary interstitial cell survival during high levels
of hypertonic stress, in response to PGI2.P P A R δ activa-
tion also protected kidneys from renal failure after renal
ischemia/reperfusion experiments via the antiapoptotic Akt
pathway [12]. Although, most of the studies have suggested
an antiapoptotic role of PPARδ, a few papers have shown
that PPARδ can increase apoptosis [13]. However, PPARδ is
recognized as an important protein in the survival of many
r e n a lc e l lt y p e s .
PPARδ has also been shown to promote growth
responses in a variety of cells. PGE2, working through
PPARδ, can stimulate proliferation of stem cells [14]
and overexpression of PPARδ has been shown to reverse
inhibitory growth signals in a prostate epithelial cell line
[15].Furthermore,upregulationofPPARδ insmoothmuscle
cells promotes cell cycle progression [16]. The eﬀect of
PPARδ activation on cell growth in the kidney, however, is
unknown.
Thecollectingduct(CD),speciﬁcallytheIMCD,survives
in a harsh environment due to the hypertonic conditions
in the interstitium needed to concentrate urine [17, 18].
In most cells, apoptosis would occur at the levels of stress
at which they reside, but the CD manages to survive and2 PPAR Research
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Figure 1: EP receptor subtypes and PPARδ are expressed in IMCD-K2 cells. RNA was isolated from IMCD-K2 cells using TRIzol, reverse
transcribed, ampliﬁed by polymerase chain reaction using primers for (a) the prostanoid receptors and (b) PPARδ receptor, and visualized
on an agarose gel using ethidium bromide under ultraviolet light. As shown, speciﬁc bands for each PCR product were obtained at the
predicted size for EP1 (336 base pair), EP3 (437 base pair; plus bands at ∼350 base pair and ∼600 base pair), and EP4 (423 base pair), as well
as PPARδ (161 base pair).
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Figure 2: PGE2 stimulates cAMP in IMCD-K2 cells.Serum-starved cells were stimulated for ten minutes with (a) 10
−6 Mo fd i ﬀerent
prostanoids (cicaprost (CCP), iloprost (ILP), and PGE2)o r1 0
−5 M forskolin (FOR), and with (b) diﬀering concentrations of PGE2 (10
−9 to
10
−6 M). A competitive binding assay with 3H-cAMP was performed and the percent cAMP stimulation was determined using a scintillation
counter. Values are means ± S.E.M.; n = 3–4. ∗P<. 05 compared to control.
resist any apoptotic activity [19]. It is known that cells react
to high levels of tonicity by increasing the transport of
several osmolytes into the cells aiding in their survival [20].
However, in cells where there is chronic hypertonicity, like
the IMCD, the accumulation of these osmolytes may not be
suﬃcient for their continued survival [21]. Cultured IMCD
cells have been known to increase levels of cyclooxygenase-2
(COX-2) and stimulate PGE2 release up to 33-fold of control
in response to hypertonic stress [22]. It is likely then that
PGs may contribute to the inherent CD resistance to stress
by targeting PPARδ to promote cell survival.
It would appear in most cell lines that PPARδ has oppos-
ing growth and apoptotic eﬀects; however, its role in the CD
has not been determined. Our study examines the role of
PPARδ activation in the survival and growth of IMCD-K2
cells.ThemouseIMCD-K2celllineisderivedfromtheinitial
portion of the IMCD from a mouse that is transgenic for
Simian Virus 40 (SV40) and was shown to retain many char-
acteristics of the intact IMCD, including amiloride-sensitive
sodium absorption stimulated by aldosterone [23]. There-
fore, we propose that PPARδ activation will regulate growth
and apoptotic responses in the mouse IMCD-K2 cells.PPAR Research 3
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Figure 3: PGE2 increases PPARδ protein expression. Protein was
isolated from IMCD-K2 cells that had been treated with serum-free
media(control,C),10
−5 Mindomethacin(Indo,I),or10
−6 MPGE 2
in the presence of I (PI) 2, 8, and 24 hours. The proteins were (a)
run on an SDS-PAGE gel and Western blotted using an anti-PPARδ
antibody (1 : 500). A representative blot of 24-hour treatment is
shown. The membranes were stripped and β-actin was detected
to normalize samples for (b) densitometric analysis. Expression is
presented as fold of control. Values are means ±S.E.M.; n = 3–6.
∗P<. 05comparedtocontrol; §P<. 05comparedtoindomethacin.
2.MaterialsandMethods
2.1. IMCD-K2 Cell Culture. Cells were obtained from Dr.
Bruce Stanton from Dartmouth Medical College (Hanover,
NH, USA). The cells were maintained at 37
◦Ca n d
5% CO2 in DMEM/F-12 supplemented with 10% fetal
bovine serum, (FBS, Gibco, Carlsbad, Calif, USA), 1% peni-
cillin/streptomycin (Gibco), ITS (5μg/mL insulin, 5μg/mL
transferrin, 5ng/mL selenium; Sigma, St. Louis, Mo, USA),
2mM L-glutamine (Sigma), and 5μM dexamethasone
(Sigma). Cell culture medium was replaced every 48 hours.
Twenty-fourhourspriortoexperiments,theculturemedium
was replaced with serum-free medium (DMEM/F-12).
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Figure 4: PGE2 does not aﬀect PPARδ mRNA expression. RNA
was isolated from IMCD-K2 cells using the TRIzol method. The
cells had been treated for 2, 8, and 24 hours with serum-free
media (control), 10
−5 M indomethacin (Indo), or 10
−6 MP G E 2
in the presence of 10
−5 M indomethacin (PI). The RNA samples
were quantiﬁed using real-time PCR using primers and probes for
PPARδ.Glyceraldehyde-3-phosphatedehydrogenase(GAPDH)was
used as an internal control. Expression is presented as the amount
of PPARδ mRNA expression divided by GAPDH expression. Values
are means ± S.E.M.; n = 5.
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Figure 5: GW501516 causes a decrease in DNA synthesis at high
doses.Serum-starvedcellswerestimulatedfor24hourswithserum-
free media (control) or increasing concentrations of GW501516
(10
−8 to 10
−5 M) 3H-thymidine was added to IMCD-K2 cells
while they were being stimulated and thymidine incorporation was
measured in counts per minute using a scintillation counter, and
expressedasfoldcontrol.Valuesaremean ± S.E.M.;n = 3. ∗P<. 05
compared to control.
2.2. Reverse Transcriptase-PCR. RNA was isolated from
conﬂuent 100mm plates of IMCD-K2 cells using 1mL of
the TRIzol reagent (Gibco) according to the manufacturer’s
instructions and then treated with DNase I (Invitrogen,
Carlsbad, Calif, USA). The RNA was reverse transcribed
using MuLV reverse transcriptase and random hexamers4 PPAR Research
0
0.2
0.4
0.6
0.8
1
1.2
3
H
-
l
e
u
c
i
n
e
i
n
c
o
r
p
o
r
a
t
i
o
n
(
f
o
l
d
c
o
n
t
r
o
l
)
Control 10−8 10−7 10−6 10−5
GW501516
∗
Figure 6: GW501516 causes a decrease in protein synthesis at high
doses.Serum-starvedcellswerestimulatedfor24hourswithserum-
free media (control) or increasing concentrations of GW501516
(10
−8 to 10
−5 M) 3H-leucine was added to IMCD-K2 cells while
theywerebeingstimulatedandleucineincorporationwasmeasured
in counts per minute using a scintillation counter, and expressed
as fold control. Values are mean ± S.E.M.; n = 3–5. ∗P<. 05
compared to control.
from the GeneAmp RNA PCR Core Kit (Applied Biosys-
tems, Foster City, Calif, USA) as per the manufacturer’s
instructions. Next, the RNA was ampliﬁed by polymerase
chain reaction (PCR), using AmpliTaq DNA polymerase
and speciﬁc primers for the prostanoid receptors (i.e., EP1–4
and IP) and PPARδ. The primers were obtained from
the University of Ottawa Biotechnology Research Institute
(Ottawa, ON, Canada). The PCR parameters used were 40
cycles of: 95◦C for 30 seconds, 59◦C for 45 seconds, and
72◦C for 60 seconds, followed by 600 seconds at 72◦C.
The ampliﬁcation was carried out using the GeneAMP PCR
System 2400 (Applied Biosystems). The PCR products were
run on an agarose gel and the bands were visualized using
ethidium bromide under UV light.
2.3. 3H-cAMP Assay. Since prostanoids can alter cAMP,
their eﬀect on cAMP production in IMCD-K2 cells was
determined. The cells were serum starved for 24 hours
and stimulated with control (serum-free media), 10
−5 M
forskolin (Sigma) as a positive control, 10
−6 M cicaprost and
iloprost (prostacyclin analogs, Schering Ag Berlin, Berlin,
Germany), or 10
−9–10
−6 M of prostaglandin E2 (PGE2,
C a y m a n ,A n nA r b o r ,M i c h ,U S A )T h ec e l l sw e r ep r e t r e a t e d
for ﬁfteen minutes with 0.5mM isobutylmethylxanthine
(IBMX, Sigma), a cAMP phosphodiesterase inhibitor, and
10
−5 M indomethacin (Sigma), a cyclooxygenase (COX)
inhibitor. The stimulation was then stopped with cold
10% trichloroacetic acid for 30 minutes on ice. Four ether
extractions were carried out, and a cAMP competitive
binding assay was done using the 3H-cAMP DPC radioassay
(Intermedico,Markham,ON,Canada)aspermanufacturer’s
instructions. The amount of 3H-cAMP was measured using
a scintillation counter (Beckman Coulter, Mississauga, ON,
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Figure 7: GW501516 does not signiﬁcantly alter IMCD-K2 cell via-
bility.Serum-starvedcellswerestimulatedfor24hourswithserum-
free media (control) or increasing concentrations of GW501516
(10
−8 to 10
−5 M). The cells were then incubated for one hour with
the DNA dye-binding solution from the CyQUANT NF assay kit
(Invitrogen). Fluorescence intensity, representing number of cells,
was then measured as per the manufacturer’s instructions. Values
(fold control) are means ± S.E.M.; n = 3.
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Figure 8: GW501516 has no eﬀect on anisomycin-induced cell
death. Serum-starved cells were stimulated with serum-free media
(control), 10
−6 M GW501516 (GW), 100 and 1000ng/mL ani-
somycin (A100 and A1000, resp.), or 50ng/mL cisplatin (Cis)
for 18 hours. Some of the cells treated with anisomycin were
pretreatedwith10
−6 GW501516for24hoursandcotreatedwiththe
agonist and anisomycin for 18 hours (GW/A100 and GW/A1000).
The cells were then incubated for one hour with the DNA dye-
binding solution from the CyQUANT NF assay kit (Invitrogen).
Fluorescence intensity, representing number of cells, was then
measured as per the manufacturer’s instructions. Values are means
± S.E.M.; n = 3. ∗P<. 05 compared to control; §P<. 05 compared
to GW.
Canada) and the percent stimulation of cAMP levels over
c o n t r o ll e v e l so fe a c hs a m p l ew a sc a l c u l a t e d .
2.4. Western Blotting. IMCD-K2 lysates were obtained by
sonicating samples in RIPA lysis buﬀer containing 1% Non-
idet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulphate (SDS, w/v), 4.5mM NaCl, 2.5mM Tris (pH 7.4),PPAR Research 5
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Figure 9: Anisomycin increases caspase activity in IMCD-K2 cells,
independent of GW501516. Serum-starved cells were treated with
serum-free media (control) for 24 hours, 250ng/mL anisomycin
(A250) for 24 hours, 10
−6 M GW501516, and 10
−8 M GW501516
for 24 hours pretreatment followed by 10
−6 Ma n d1 0
−8 M
GW501516 for 24 hours with (GW-6/A250 and GW-8/A250) or
without anisomycin (GW-6 and GW-8), Z-VAD-FMK, a pan-
caspase inhibitor with (Z/A250) or without (Z) anisomycin. Values
are mean ± S.E.M.
8μM EDTA, 0.2mM sodium phosphate (pH 7.2), and fresh
0.5mM PMSF, 1 : 100 protease inhibitor cocktail (Sigma),
1mM sodium pyrophosphate, 10mM sodium ﬂuoride, and
100μM sodium orthovanadate. The protein was quantiﬁed
using the Bradford reagent method (Bio-Rad, Hercules,
Calif, USA). The lysates were then resolved by SDS-PAGE on
a polyacrylamide gel using a Mini-PROTEAN II apparatus
(Bio-Rad) and transferred onto nitrocellulose membranes
(Amersham, Amersham, UK). After blocking for 90 minutes
in 10% milk/TBS-T (137mM NaCl, 20mM Tris base, 0.1%
Tween20),themembraneswereincubatedovernightwiththe
corresponding primary antibody. The membranes were then
incubated with their respective secondary antibodies (i.e.,
anti-rabbit, anti-mouse, and anti-donkey) for 90 minutes
and then washed for 60–90 minutes in TBS-T. The bands
were then visualized by ECL. Detection of β-actin was used
tonormalizesamplesanddensitometricanalysisofthebands
was performed using the Kodak 1D Image Analysis software
(Eastman Kodak Company, Rochester, NY, USA).
2.5. Real-Time PCR. To determine the eﬀect of PGE2 on
PPARδ levels in IMCD-K2 cells, RNA was isolated and
DNase-treated as described above. The cells were treated for
2, 8, or 24 hours with serum-free media as control, 10
−5 M
indomethacin, or 10
−6 MP G E 2. A ﬁfteen-minute pretreat-
ment with indomethacin was performed prior to stimula-
t i o n sw i t hP G E 2 and forskolin. The mRNA levels of PPARδ
were ascertained by real-time PCR using TaqMan One-Step
RT-PCR master mix reagents (Applied Biosystems) and an
ABI Prism 7000 sequence detection system. Reactions were
carried out by using 50ng of total IMCD-K2 RNA under the
following conditions: 48◦Cf o r3 0m i n u t e s ,a n d9 5 ◦Cf o r1 0
minutes, and 40 cycles of 95◦Cf o r1 5s e c o n d sa n d6 0 ◦Cf o r
1 minute. The probe and primers used for mouse PPARδ
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Figure 10: Pretreatment with GW501516 does not signiﬁ-
cantly alter anisomycin-induced cleaved caspase-3 protein in
IMCD-K2 cells. Protein was isolated from IMCD-K2 cells that
had been treated with control serum-free media, 10
−6 or
10
−8 M GW501516, 250ng/mL anisomycin (A250 or A) for 24
hours, 10
−6 M GW501516 for 3 hours pretreatment followed by
10
−6 M GW501516 for 24 hours with A250 (GW-6/A250), or
10
−8 M GW501516 for 3 hours pretreatment followed by 10
−8 M
GW501516 for 24 hours with A250 (GW-8/A250). (a) The lysates
were run on an SDS-PAGE gel and incubated with an anticleaved
caspase-3 antibody (1 : 1000). (b) The membranes were stripped
and incubated with anti-β-actin antibody (1 : 10000) to normalize
for densitometry. Expression is presented as fold A250. Values are
mean ± S.E.M.; n = 8.
were forward primer, 5 -GAGCCCAAGTTCGAGTTTGC-
3 , reverse primer, 5 -TGAAGAGCGCCAGGTCACT-3 ,a n d
probe, FAM-AGTTCAATGCGCTGGAGCTCGATGA-TAM
(Sigma Genosys, Oakville, ON, Canada). All values were
normalized to GAPDH mRNA levels in the same sample,
which was determined by the TaqMan Rodent GAPDH
control reagent kit (AppliedBiosystems).
2.6. 3H-Thymidine Incorporation. To study the eﬀect of
the PPAR activation on cell proliferation, DNA synthesis
was measured using the incorporation of 3H-thymidine.
IMCD-K2 cells were cultured in 24-well plates, grown to
∼50% conﬂuence, and then starved with serum-free media.
Afterwards the cells were treated for 24 hours with vehicle-
treated control (DMSO), or GW501516 (10
−8,1 0
−7,1 0
−6,
10
−5 M). GW501516 is among the more speciﬁc and most
commonlyusedsyntheticPPARδ ligands[24]. 3H-thymidine6 PPAR Research
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Figure 11: GW501516 pretreatment has no eﬀect on anisomycin-induced apoptosis. Serum-starved cells were stimulated with (a)–(c)
serum-free media (control), (d)–(f) 10
−6 M GW501516 (GW-6), (g)–(i) 10
−8 M GW501516 (GW-8), (j)–(l) 250ng/mL anisomycin (A250)
for24hours,(m)–(o)10
−6 M,or(p)–(r)10
−8 MGW501516for3hourspretreatmentfollowedby10
−6 Mor10
−8 MGW501516for24hours
with A250 (GW-6/A250 and GW-8/A250). The cells were incubated with terminal transferase and biotin-16-dUTP for one hour, followed
by two 45-minute incubations with streptavidin-Cy2 and anti-DAPI. The cells were then mounted on slides, visualized with a ﬂuorescent
microscope, and captured with a camera. Apoptotic cells are shown in green, while the blue represents DAPI-positive cells.PPAR Research 7
(Amersham, 0.5μCi/mL) was added during the ﬁnal four
hours of stimulation. The plates were then washed four
times in ice-cold PBS. Next, the cells were permeabilized
in 500μL of 1N NaOH at 37◦Cf o r∼30 minutes, and the
amount of 3H-thymidine in counts per minute (cpm) was
measured using a scintillation counter. Samples were done in
triplicate and thymidine incorporation is expressed as fold
control.
2.7. 3H-Leucine Incorporation. To study the eﬀect of the
PPAR ligands on cell growth, protein synthesis was measured
using the incorporation of 3H-leucine. IMCD-K2 cells were
cultured in 24-well plates, grown to ∼50% conﬂuence, and
then starved with serum-free media for 24 hours. Next
the cells were stimulated for 24 hours with vehicle-treated
control (DMSO) and GW501516 (10
−8,1 0
−7,1 0
−6,a n d
10
−5 M). 3H-leucine (Amersham, Perkin Elmer, Waltham,
Mass, USA, 0.5μCi/mL) was added to each well during
the 24-hour stimulation. The cells were then prepared as
described above and the amount of 3H-leucine in counts per
minute was measured using a scintillation counter. Samples
weredoneintriplicateandleucineincorporationisexpressed
as fold control.
2.8. Cell Viability. To evaluate the eﬀect of GW501516 on
the viability of IMCD-K2 cells in both the presence and
absence of a death response, a cell viability assay was
performed.IMCD-K2cellsweregrownto70%conﬂuencein
96-well plates and stimulated for 18 hours with control (1μL
of ethanol and 1μL DMSO in DMEM/F-12), GW501516
(10
−8,1 0
−7,5× 10
−7,1 0
−6,5× 10
−6,a n d1 0
−5 M),
anisomycin (Sigma; 100, 1000ng/mL), or cisplatin (Sigma;
50ng/mL). Some cells were treated with both anisomycin
and GW501516 (10
−6 M) following a 24-hour pretreatment
with GW501516 (10
−6 M). Anisomycin and cisplatin were
used to induce cell death. Following the stimulation, the cells
were incubated in 100μL of a 1x DNA dye-binding solution
from the CyQAUNT NF kit (Invitrogen). The ﬂuorescence
intensity, representing the number of cells, was measured
in a FLUOstar Galaxy plate reader (BMG Labtechnologies,
Durham, NC, USA). Samples were done in triplicate and
ﬂuorescence intensity is expressed as fold control.
2.9. Colorimetric Caspase-3 Activity Assay. To determine if
GW501516 is involved in apoptosis, a caspase-3 activity
assay was carried out using the colorimetric CaspACE Assay
System kit (Promega, Madison, Wis, USA), as per manu-
facturer’s instructions. IMCD-K2 cells were grown to ∼50%
conﬂuence in 100mm plates and starved for 24 hours. Next
the cells were treated with control (1μL of ethanol and 1μL
of DMSO in 1mL of DMEM/F-12), 10% FBS, GW501516
(10
−6 M), anisomycin (250ng/mL), or Z-VAD-FMK (2 ×
10
−5 M), a pan-caspase inhibitor supplied in the kit. Some
cells were treated with both anisomycin and GW501516
following a 24-hour pretreatment with GW501516. Also,
some plates were treated with anisomycin and Z-VAD-
FMK following a 24-hour pretreatment with the inhibitor.
Following stimulations, the cells were resuspended in 100–
200μL of the caspase lysis buﬀer subjected to two freeze-
thaw cycles (at −20◦C), and a 15-minute incubation on ice.
The lysates were then centrifuged for 20 minutes at 13100
revolutions per minute and protein was quantiﬁed using the
Bradford method. 50μg of each sample was incubated with
the colorimetric caspase-3 substrate Ac-DEVD-pNA (2 ×
10
−4 M) in a 96-well plate at room temperature overnight.
The endogenous active caspase-3 bound to the substrate was
determinedbytheabsorbanceat405nm(FLUOstarGalaxy).
Samples were done in duplicate and the caspase activity is
e x p r e s s e da sr e l a t i v ea b s o r b a n c e .
2.10. TUNEL Assay. To further evaluate the eﬀect of
GW501516 on apoptosis, a terminal deoxynucleotidyl trans-
ferase biotin-dUTP nick end labeling (TUNEL) assay was
performed. IMCD-K2 cells were grown to ∼60% conﬂuency
on glass coverslips in a 24-well plate and treated in duplicate
for 24 hours with control (1μL of ethanol and 1μLo f
DMSOin1mLofDMEM/F-12),GW501516(10
−8,10
−6 M),
or anisomycin (250ng/mL). Some cells were treated with
both GW501516 (10
−8,1 0
−6 M) and anisomycin, following
a 3-hour pretreatment with the respective concentrations of
GW501516. After the stimulation, the cells was ﬁxed in 4%
paraformaldehyde and 0.2% picric acid in 0.16M sodium
phosphate buﬀer (pH 6.9). The coverslips were then washed
with PBS three times and incubated with 2μLC o C l 2,5μL
5X TDT buﬀer, 0.1μL terminal transferase (all taken from
the Roche Terminal Transferase recombinant kit), 0.17μL
biotin-16-dUTP (Roche, Mississauga, ON, Canada), and
17.73μLo fH 2Of o r1h o u ra t3 7
◦Ci nah u m i dc h a m b e r .
Next,thecellswerewashedwith4XSSC(0.6MNaCl,76mM
Na Citrate, pH 7), blocked for 30 minutes with 1% milk/4X
SSC at room temperature, and incubated with streptavidin-
Cy2 (Molecular Probes,Carlsbad, Calif, USA, 1.0mg/mL) at
1 : 1000 for 45 minutes at room temperature in the dark.
The coverslips were then washed with PBS and incubated
with DAPI for 45 minutes at 1 : 1000. Following three
morewashes,thecoverslipswereinverted ontoFluoromount
mounting media (Electron Microscopy Sciences, Hatﬁeld,
Pa, USA) on glass slides. The cells were visualized with the
ﬂuorescent microscope Axioskop Mot 2 (Zeiss, Oberkochen,
Germany) and captured with the camera AxioCam (Zeiss).
For each coverslip, 8 ﬁelds of view at 200x magniﬁcation
were examined using pictures from both the DAPI ﬁlter
(excitation: ∼360nm and emission: ∼450nm) and the
green ﬁlter (excitation: ∼480nm and emission: ∼540nm).
The pictures were processed using the Axiovision software
(Zeiss).Theterminaltransferaseandbiotin-16-dUTPtarget-
free DNA fragments of apoptotic cells produce a ﬂuorescent
green signal. The number of apoptotic cells was counted,
and from the DAPI ﬁlter a percentage of TUNEL-positive
cells were determined. A total of 16 ﬁelds of view, or two
coverslips, were used for each sample.
2.11.Statistics. TheGraphPadPrismsoftware(LaJolla,Calif,
USA) for Windows (version 4.02) was used to analyze data.
Results are expressed as means ± standard error of the mean8 PPAR Research
(S.E.M). Either an unpaired t-test or a one-sample t-test
(with a hypothetical value of 1) was used to evaluate the
statistical signiﬁcance between data points. A P-value <. 05
was considered statistically signiﬁcant.
3. Results
3.1. EP Receptor Subtypes and PPARδ Expression. PGE2 is
known to activate prostanoid receptors, EP1,E P 2,E P 3,a n d
EP4 as well as PPARδ. Thus, the presence of these receptors
in IMCD-K2 cells was determined. PCR was performed
and bands corresponding to the prostanoid and PPARδ
receptors were visualized as shown in Figures 1(a) and 1(b),
respectively.Previousstudiesinourlaboratorydemonstrated
that at higher stringency the band in the EP2 lane disappears
and that the product detected with the IP primers, present at
approximately 200 base pair (bp) greater than the predicted
size of 407bp, does not correspond to the IP receptor,
as determined by cloning and sequencing. The band seen
between 700 and 800bp in the EP1 lane represents protein
kinase N (PKN), as the genes for PKN and EP1 overlap
[25]. The multiple bands seen in the EP3 are most likely due
to alternative splicing of the EP3 gene [26]. The products
were not present when the reverse transcriptase was omitted
(negative control; data not shown). These results indicate
that IMCD-K2 cells express EP1,E P 3,E P 4,a n dP P A R δ.
3.2. Eﬀect of PGE2 on cAMP Stimulation. Both the EP3 and
EP4 receptors elicit changes in intracellular cAMP; therefore,
the eﬀect of diﬀerent prostanoids on cAMP stimulation was
examined.Forskolinwasusedasapositivecontrol.Asshown
in Figure 2(a), prostacyclin (PGI2) analogs cicaprost (CCP)
and iloprost (ILP) did not alter cAMP levels. PGE2,h o w e v e r ,
did cause a signiﬁcant increase in percent stimulation, at
about70%abovecontrol,comparabletoforskolin.Asshown
in Figure 2(b), treatment with increasing amounts of PGE2
resulted in a concentration-dependent increase in cAMP,
from 14.0 to 85.5%.
3.3. The Eﬀect of PGE2 on PPARδ Expression. Since PGE2
has been known to activate PPARδ to regulate several
growth processes [7, 14], it was ascertained that if PGE2
stimulation could aﬀect PPARδ expression in IMCD-K2
cells. Indomethacin, a COX inhibitor, was used to inhibit
endogenousPGsynthesis.AsshowninFigures3(a)and3(b),
treatment with PGE2, in the presence of indomethacin, for 8
hours resulted in a signiﬁcant increase, of ∼2-fold, in PPARδ
protein expression compared to control or indomethacin
alone, as measured by Western Blotting. Stimulation for 24
hours also resulted in increased PPARδ protein expression,
but this increase was not signiﬁcant when compared with
indomethacin alone. A representative blot for 24 hours is
shown in Figure 3(a). However, two-hour stimulation did
not alter the protein levels of PPARδ. We also examined
the eﬀect of PGE2 on PPARδ mRNA expression by real-
time PCR. As shown in Figure 4,P P A R δ mRNA remained
unchanged with any treatment group or exposure time.
Forskolinhadnoeﬀectonexpressioneither(datanotshown)
indicating that cAMP does not alter PPARδ protein or RNA
expression.
3.4. The Eﬀect of GW501516 on Cell Proliferation/Growth.
PPARδ has been known to aﬀect cell proliferation; therefore,
we studied the eﬀect of the PPARδ agonist, GW501515, on
the proliferation/growth of IMCD-K2 cells. As shown in
Figure 5,1 0
−5 M GW501516 reduced 3H-thymidine incor-
porationtoabout0.05-foldcontrol.PPARδ alsoregulatescell
growth and as shown in Figure 6,1 0
−5 M GW501516 pro-
duced a signiﬁcant reduction in 3H-leucine incorporation
to approximately 0.19 of control. At lower concentrations of
GW501516, neither DNA nor protein synthesis was altered.
3.5. The Eﬀect of GW501516 on Cell Viability. To further
characterize the eﬀect of GW501516 on IMCD-K2 cells and
determine if it has a role in cell survival, a cell viability assay
was carried out. As shown in Figure 7, GW501516 (10
−8,
10
−7,5×10
−7,1 0
−6,5×10
−6,a n d1 0
−5 M) caused a decrease
in cell viability between 0.8 and 0.6-fold of control but none
of the values was signiﬁcant. On its own, GW501516 did not
induce death in the IMCD-K2 cells. To examine if the PPARδ
agonist could protect cells from an induced death, IMCD-
K2 cells were treated with both anisomycin and GW501516.
Cisplatin (cis-diamminedichloridoplatinum[II]) was used as
an additional positive control for cell death. As shown
in Figure 8, anisomycin (100 and 1000ng/mL) caused cell
viability to decrease to approximately 0.46- and 0.37-fold of
control, respectively. However, 10
−6 M GW501516 did not
signiﬁcantly alter the decrease in cell viability seen with the
addition of either 100 or 1000ng/mL of anisomycin.
3.6. The Eﬀect of GW501516 on Caspase Activity. Besides
having eﬀects in cell growth, PPARδ has also been linked
to changes in apoptosis. Therefore, the antiapoptotic eﬀect
of GW501516 was evaluated in IMCD-K2 cells. Caspase-3
activity was examined because it is a downstream eﬀector
protease that is common to all apoptotic pathways. As
shown in Figure 9, anisomycin treatment resulted in an
increase of caspase-3 levels of about 2.59-fold of control.
Pre/cotreatment with GW501516 showed a decrease that was
0.79-fold (10
−6 M) and 0.81-fold (10
−8 M) of anisomycin
alone. GW501516 alone showed no considerable change in
caspase activity. The caspase inhibitor, Z-VAD completely
abolished caspase activity in unstimulated cells, and in
anisomycin-treated cells it decreased caspase activity to 0.06-
fold of anisomycin alone.
Activation of caspase was also measured by Western
Blotting using a cleaved caspase-3 antibody. As shown
in Figure 10(a), a 17kDa band corresponding to cleaved
caspase-3 was observed for the lysates that had been treated
with anisomycin. The intensity of the bands in the lanes
representing control and GW501516 alone was too low to
be analyzed in the majority of the experiments; therefore,
densitometric analysis was not performed for those samples.
T h el e v e l so fa c t i v ec a s p a s e - 3( s e eFigure 10(b)) increased to
1.48 and 1.18 of anisomycin alone with both cotreatmentsPPAR Research 9
(10
−6 and 10
−8 M GW501516, resp.) but the diﬀerence was
not signiﬁcant.
3.7. The Eﬀect of GW501516 on Apoptosis. In addition to
looking at the eﬀect of GW501516 on caspase activity,
TUNEL assays were performed to further evaluate the
apoptotic response. As shown in Figure 11, the proportion
of TUNEL-positive cells increased while the total number of
cells decreases with the addition of 250ng/mL anisomycin
when compared to control or the PPARδ agonist (at
both concentrations). Pre/cotreatment of 10
−6 Mo r1 0
−8 M
GW501516 with anisomycin was comparable to anisomycin
alone.
4. Discussion
4.1. PGE2 and PPARδ. It has been shown previously that
prostaglandins, including PGE2, and PPARs inﬂuence one
another’s activity [27–30]. Although our studies showed that
the PGE2 receptors EP1,E P 3,a n dE P 4 are present in the
IMCD-K2 cells and PGE2 produces an increase in cAMP
production, consistent with the expression of EP4,P G E 2 had
no eﬀect on PPARδ mRNA expression. However, treatment
with PGE2 for eight hours did elicit an increase in PPARδ
protein levels. There are two likely explanations for this. The
ﬁrst reason is that the PPARδ protein could be stabilized. A
previous study in a prostate cancer cell line has shown that
PGE2 can stabilize hypoxia-inducible factor 1 alpha (HIF-
1α) protein levels, without aﬀecting mRNA levels [31]. This
would most likely be due to PGE2 preventing proteolysis
of PPARδ. Interestingly, it has been revealed that unlike
most nuclear receptors, degradation of PPARδ does not
occur upon ligand binding but is in fact inhibited by it
[32]. This would indicate that PGE2 could be causing an
increase in PPARδ activation. The second possible role of
PGE2 is that it could be enhancing the translation of basal
PPARδ mRNA levels or stabilizing it. The ability of PGE2 to
stabilizemRNA(interleukin8)hasbeenpreviouslydescribed
in a paper by Yu and Chadee [33]. Therefore, from the
results reported here and the literature, the eﬀect of PGE2
on PPARδ is most likely a posttranscriptional event. We also
observed an increase in PPARδ p r o t e i ni nr e s p o n s et o2 4
hours indomethacin. It is not clear at this time whether this
eﬀect is due to a direct increase in expression, but it has
previously been shown that PPAR expression is altered by
NSAIDs [34].
4.2. PPARδ Agonist and Cell Proliferation/Growth in IMCD-
K2 Cells. It has been previously reported that activation of
PPARδ and the use of PPARδ ligands promote cell survival
and proliferation. One recent study, using both PPARδ short
interfering RNA (siRNA) and a PPAR antagonist, showed
that downregulation or blocking the activation of PPARδ,
respectively, inhibited the PGE2-induced proliferation of
mouse embryonic stem cells [14]. Another study revealed
that a PPARδ agonist can stimulate propagation in both
human and mouse aortic endothelial cells [35]. However,
the eﬀects of PPARδ o nr e n a lc e l lg r o w t hr e s p o n s e sh a v e
not been characterized. Here we show that a highly speciﬁc
PPARδ ligand, GW501516, decreased DNA and protein
synthesis in IMCD-K2 cells, but only at high concentrations.
Although most studies indicate that PPARδ activationresults
in stimulation of cell growth, mostly in human and mouse
colon cancer cells [7, 36], there have been previous ﬁndings
showing that PPARδ agonists, including GW501516, can
hinder or have no eﬀect on cell growth in certain human
breastcancercellsandmelanomas[37,38].Thesediﬀerences
m a yb ed u et os p e c i e sd i ﬀerences or diversity among cell
lines.
4.3. PPARδ Agonist and Anisomycin-Induced Apoptosis in
IMCD-K2 Cells. Another ﬁnding in our study is that treat-
ment with GW501516 does not reverse the reduction in
cell survival due to exposure to anisomycin. These results
are inconsistent with the literature that demonstrates that
activation of PPARδ, or the use of a PPARδ agonist, protects
many diﬀerent cell types, including renal cells [12]. It is
possible that the agonist may not actually be activating
PPARδ in IMCD-K2 cells, as its eﬃcacy in this cell line
has never been tested. In addition, PPARδ activation may
not be aﬀecting cell survival if the death response is mostly
through necrosis because studies only show a survival role
forPPARδ withregardtoapoptosis.Toevaluateiftheagonist
is having an eﬀect on PPARδ activation, experiments can
be performed with cells transfected with a PPRE-driven
reporter plasmid [39]. To completely assess death pathways
activated by anisomycin, ﬂow cytometry using the annexin
V-FITC and propidium iodide stains should be used [40].
Even though the use of the agonist, in our experiments,
elicits no response in overall cell survival in IMCD-K2 cells,
the eﬀect on apoptosis had yet to be investigated. When the
CD is in a disease state due to urinary tract obstruction,
ischemia-reperfusion injury or other insults apoptosis levels
tend to increase [41, 42]. Thus, we wished to examine if
PPARδ could protect the CD from apoptosis. Using a variety
of experiments assessing apoptosis (caspase activity assay,
Western blotting, TUNEL), we found no signiﬁcant change
in the levels of apoptosis in cells treated with GW501516
compared to those stimulated with just anisomycin. The
variation between our data and the majority of the literature
could be due to diﬀerences in cell types and the condition
of the cells, as most studies have focussed on colorectal
cancer tissues [7, 8, 43, 44]. It seems unlikely that the
discrepancy in PPARδ eﬀects is due to species diﬀerences as
most of the cancer studies were done using mouse tissues.
However, a few studies clearly indicate that PPARδ may not
provide any prevention in certain types of apoptosis, such
as in the L´ opez et al. [45] study where overexpression of
PPARδ did not protect against aspirin-induced apoptosis in
Jurkat cells. Thus, it is possible that PPARδ m a yo n l yp r o t e c t
cells from apoptosis in certain conditions and cell types.
From the data we collected, GW501516 has no eﬀect on
cell survival or anisomycin-induced apoptosis. The IMCD
and possibly the IMCD-K2 cells are resistant to cell death
because their environment in vivo is one of hypertonicity
[46]. This inherent resiliency may make them resistant to10 PPAR Research
diﬀerent treatments, similar to that previously observed in
a mouse IMCD cell line [47].
4.4. Summary. The main objective of this study was to
determine whether PPARδ regulates growth and apoptosis in
IMCD-K2 cells. PPARδ is highly expressed in the CD, and
thus may be responsible for the protection of the CD. We
showed that growth responses, including DNA and protein
synthesis, in these cells are reduced by PPARδ ligands, but
only at high doses. GW501516 had no eﬀect on anisomycin-
induced apoptosis in the IMCD-K2 cell line.
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